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Abstract (word count 200)
Conclusion
Transcutaneous vagal nerve stimulation (tVNS) might offer a targeted, patient-friendly and
low-cost therapeutic tool for tinnitus patients with sympathovagal imbalance.
Objectives
Conventionally, VNS has been performed to treat severe epilepsy and depression with an
electrode implanted to the cervical trunk of vagus nerve. In this study we investigated the
2acute effects of tVNS on autonomic nervous system (ANS) imbalance, which often occurs
in patients with tinnitus-triggered stress.
Methods
We retrospectively analysed records of 97 patients who had undergone ANS function
testing by heart rate variability (HRV) measurement immediately before and after a 15 to
60 min tVNS stimulation.
Results
The pretreatment HRV recording showed sympathetic preponderance/reduced
parasympathetic activity in about three quarters (73%) of patients. Active tVNS
significantly increased variability of R-R intervals in 75% of patients and HRV age was
decreased in 70% of patients. Either the variability of R-R intervals was increased or the
HRV age decreased in 90% of the patients. These results indicate, that tVNS can induce a
shift in ANS function from sympathetic preponderance towards parasympathetic
predominance. tVNS caused no major morbidity and heart rate monitoring during the tVNS
treatment showed no cardiac or circulatory effects (e.g. bradycardia) in any of the patients.
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INTRODUCTION
Patients with severe tinnitus often show associated symptoms, which have features of
autonomic dysfunction. These stress-related symptoms are characterized by excessive
sympathetic activation and concomitant reduced parasympathetic activation. This type of
autonomic imbalance is often manifested as a reduction in heart rate variability (HRV),
which can be measured [1].
In general terms, stress is a state of imbalance between what is required and what is
possible. As a consequence, autonomic nervous system (ANS) being in charge of the
regulation of most of physiological processes, will become overloaded. Therefore, in
mental stress, several physiological processes of the body are affected. When a person is
exposed to a stressor (like annoying tinnitus), a stress reaction can be triggered [2]. Stress
reaction from tinnitus, similarly to that from other stressors, changes the ANS balance: the
parasympathetic nervous system is suppressed and the sympathetic nervous system is
activated [3,4]. This results in the secretion of the hormones epinephrine and
norepinephrine into blood stream, which leads to, for example, vasoconstriction of blood
vessels, increased blood pressure, increased muscle tension and an increase in heart rate
and decrease in HRV. This process is known as the ‘fight-or-flight’ reaction. When the
stressor is no longer present, a negative feedback system stops cortisol production in the
body, and a sympathovagal balance is established through homeostasis between the
parasympathetic (vagal) and sympathetic system. The two circuits are constantly
interacting and this interaction is reflected in HRV. Therefore, HRV provides a measure to
express ANS activity, and may consequently provide a measure for stress [1,3].
Furthermore, HRV testing of the affected individual can indirectly be seen as a source of
information on the overall severity of the problem that is caused by tinnitus. We also
suggest that tinnitus-triggered stress is a valuable model system to investigate mental
stress and its treatment.
We have earlier investigated tinnitus-related mental stress (TRMS) clinically using stress
questionnaires and with an eMotion HRV scanner in a small series of patients with severe
or moderate tinnitus. We found that most of those patients had a significant mental stress
4associated with poor HRV [Ylikoski J, personal communication]. It was also shown, that
when the patients were treated with transcutaneous vagal nerve stimulation (tVNS) for 45-
60 minutes, the HRV was improved in more than 80% of the patients. Thus, tVNS seemed
to reduce TRMS.
Vagus nerve stimulation (VNS) has become an established therapy for difficult-to-treat
epilepsy during the past 20 years [5]. Vagus nerve provides a unique therapeutical
entrance to the brain. Electrical stimulation of this structure in the cervical region – that is
the conventional VNS method - allows direct modulative access to subcortical brain areas.
The antiepileptic effects of tVNS have been attributed to several processes such as
decreased synchrony of synaptic activities in cortical regions, increased synaptic activities
in components of the central autonomic system, and decreased synaptic activity in
components of the limbic system, such as the amygdala and the hippocampus. And finally,
VNS therapy results in intermittently increased release of multiple neuromodulators,
including acetylcholine, norepinephrine, serotonin, and brain derived neurotrophic factor
[6-7]. All these regions are either innervated directly by the vagus nerve or indirectly
through the nucleus of the solitary tract [5].
The methodology of VNS used in epilepsy and depression is an invasive procedure.
However, there exists an afferent sensory branch of the vagus nerve, which innervates the
outer ear canal and parts of the auricle. This auricular branch of the vagus nerve (ABVN),
projects centrally to the nucleus of the solitary tract in the brainstem. It has been
demonstrated by fMRI and EEG recordings that tVNS of ABVN activates the central vagal
pathways similarly as implanted VNS [8-10]. Therefore, the stimulation of ABVN might be
an easy and noninvasive method to be used for patients to obtain the beneficial effects of
vagal system activation. The medial part of tragus and concha region has been the target
area for tVNS.
Based on our earlier studies and on the recent research we have developed our tinnitus
management strategies. The aim has been firstly, to relieve stress reaction of the patient
and thus to prevent more serious mood disorders and secondly, to correct failed auditory
function of critical neuronal network through induction of activity-dependent neuronal
plasticity. Our pilot study shows that this strategy might be beneficial for tinnitus patients
[11].
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clinical experience achieved during one year with the use of HRV testing combined with a
short-term tVNS in patients with moderate or severe tinnitus-triggered mental stress.
Patients and Methods
This is a retrospective study on a cohort including 97 patients (44 male and 56 female; age
range from 18 to 70 years) with acute or exacerbated chronic tinnitus. All patients had
been diagnosed with moderate to severe tinnitus defined by a Tinnitus Handicap Inventory
Questionnaire (THI) score >32 and mini tinnitus questionnaire (mini-TQ) and were
recruited at the Tinnitus Clinic of Helsinki Ear Institute, Helsinki Finland between
November 2014 and December 2015. Baseline tinnitus profile values were: THI: 32-100,
mean 58, mini-TQ: 10-24, mean 14 (Table 1). Average tinnitus loudness was 62/100
(VAS), annoyance 70/100 (VAS) and awareness 71%.
All patients had been tested with the HRV test after which they underwent a 15-60 minute
test trial with tVNS. During this trial the heart rate was monitored and then a new HRV test
was performed. As there were no adverse effects, all the tested patients were then
instructed to use the tVNS device at home.
HRV test and heart rate monitoring
For analyzing dynamics of HRV signals (R-R intervals) the eMotion HRV measurement
system (Mega Electronics Ltd, Kuopio, Finland) was used [12]. Stress test with a HRV
scan was performed with the patient breathing with a parasympathic stimulating
respiratory rate during which the R-R interval variability was registered by wrist electrodes
with a one-lead ECG. In eMotion HRV measurement artefacts and interruptions were
effectively eliminated with high-end technology (and disposable surface electrodes) [12].
As there is no need for a strap around the chest, eMotion HRV overcomes all common
problems and disadvantages associated with chest strap based measurements. During
tests and heart-rate monitoring the patients were sitting comfortably in an armchair. Only
tests with 100 % measurement quality in the ECG monitoring were used for evaluation.
The measurement quality was automatically calculated by the HRV scanner for every test
6using the following algorithm: the heart rate curve of every test was subdivided into small
segments, which were scanned for implausible changes of the heart rate and missing
beats. The percentage of segments without disturbances in relation to the total number of
segments yielded the test quality. It ranged from 0 to 100 %. HRV parameters were
computed by the HRV scanner for ECG. The R wave was detected by means of an
adaptive ECG algorithm using the second derivative of the ECG signal. For the spectral
analysis, R-R intervals were linearly interpolated with an interpolation frequency of 5 Hz
and subsequently analyzed through a fast Fourier transformation algorithm. The obtained
spectrum could be further decomposed into separate components, which is especially
advantageous in HRV applications where Low Frequency (LF) and High Frequency (HF)
components are generally aimed to be distinguished. Sampling frequency was 1000 Hz,
accuracy 1 ms [12,13].
The following HRV parameters were measured during one-minute deep-breathing tests
(one-min DBT): mean heart rate (HR), amplitude, and ratio of heart rate oscillation (E-I
difference, E/I ratio) (E-I = difference between the highest and the lowest heart rate within
a breathing cycle), RMSSD (root means square of successive differences), SDNN
(standard deviation of the R-R intervals), and Power LF (LF = low frequency; 0.04–0.15
Hz). One-minute DBT was followed by a five-minute short-term HRV (s-HRV), where the
HRV parameters HR, SD1 (= “width” of the Poincare plot, reflecting short term variability),
SD2 (“length” of the Poincare plot, reflecting short term variability), SDNN, Stress Index,
Power HF (HF = high frequency; 0.15–0.4 Hz), Power LF, Power VLF (very low
frequency), and Total Power, were determined as well. Parameters were compared
through correlation analysis and agreement analysis by Bland-Altman plots.
The test protocol of s-HRV test was slightly modified during the measurements in this
series. Therefore, this report includes s-HRV results only from 28 patients, which were
tested with the newest protocol modification.
The results of HRV tests were evaluated on the basis of eMotion tests performed in normal
individuals [12,14,15]. The values of s-HRV were expressed as the stress index. HRV was
evaluated as good when the stress index was between 60 and 120. The upper limit of
normal stress index was 200 and stress index values up to 800-1000 indicate a
catastrophically poor parasympathetic function. HRV decreases also naturally with
7advancing age [16]. Test results were evaluated and graphically expressed as ”HRV age”
based also on test data from normal individuals [12,14,15].
tVNS neurostimulating device
A tVNS instrument consisting of one ear clip electrode connected to a wired
neurostimulating device (”SaluSTIM”, Vagus Medical Inc, Helsinki, Finland) was used.
The clinical efficacy of tVNS requires activation of thick myelinated afferent fibers of the
vagus nerve. The fibers of a sensory peripheral nerve such as the auricular branch of the
vagus nerve (ABVN) mediate touch sensation. Consequently, the stimulus intensity of
tVNS will be individually adjusted to a level above the individual’s detection threshold and
clearly below the individual’s pain threshold. The tVNS device offers a stimulus intensity
between 0.1 and 130mA with a stimulation frequency of 25 Hz, and pulse duration of 250
μs. The 15-60 minute test stimulation was performed under medical supervision in the
office so that the heart rate was continuously monitored. After the initial 15-60 minute test
stimulation, the patients were instructed to use the tVNS device at home for stimulation for
60-90 minutes daily during five days a week.
Statistical analyses
All continuous data were displayed as the mean with the standard deviation and are
compared using the paired Student’s t–test or the two sample Student’s t–test when
appropriate. In addition the effect sizes for these contrasts are reported to estimate the
clinical significance according to Cohen (D 0.2 small, 0.5 medium, 0.8 high). Statistical
analyses were done in a two-step-approach for the whole sample. Statistical significance
was assumed for a p-value <0.05.
Results
The pretreatment one-minute deep-breathing HRV recording showed lowered resting HRV
indicating sympathetic preponderance in 73% of the patients (Table 2). This was
characterized by averaged R-R interval variability showing the value of 802 and averaged
HRV age (64 years), which was higher than the chronological age (48 years) (Table 2).
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the averaged HRV age as measured by one-min deep-breathing HRV test immediately
after the tVNS test stimulation (Figures 1 and 2). tVNS increased HRV as measured by R-
R interval variability in 73 (75%) out of the 97 patients (Figure 1). In 20% HRV was
decreased and in 5% it remained unchanged.  Active tVNS decreased HRV age in 68
(70%) patients, increased it in 16% and HRV age remained unchanged in 14% of the
patients (Figure 2). Either the variability of R-R intervals was increased or the HRV age
decreased in 87 (90%) of the patients.
The results of s-HRV test in 28 patients showed a pretreatment stress index value of 249
(upper limit of normal is 120) indicating sympathetic preponderance. The tVNS reduced
this stress index to a value of 163.
When different parameters of HRV were presented graphically with good parasympathetic
function represented by a large triangle and poor parasympathetic function as a very small
triangle, the average HRV values of tested patients showed a rather small triangle which
was then significantly enlarged after tVNS stimulation (Figure 3).
tVNS caused no major morbidity and heart rate monitoring during the tVNS treatment
showed no cardiac or circulatory effects (e.g. bradycardia) in any of the patients.
Discussion
The main problem of patients with disturbing moderate or severe tinnitus is tinnitus-related
mental stress (TRMS) [2], which is associated with imbalance of the autonomic nervous
system (ANS) with sympathetic preponderance and corresponding reduced
parasympathetic activity [3,4]. Therefore, the optimal treatment of TRMS would be by
trophotropic (parasympathetic activity enhancing) means. This could be achieved by
general relaxation generating methods such as biofeedback, yoga, cognitive behavioral
therapy and relaxing music. As vagal nerve is responsible for the parasympathetic function
its stimulation might also be a novel possibility to restore the ANS balance. These results
indicate that most of the patients with moderate or severe tinnitus show sympatic
preponderance and that tVNS may increase the parasympathetic activity and it seems to
9reduce TRMS. It is also worth noting that no treatment-related adverse effects were
observed in this patient population.
In our earlier study on a series of 24 patients we also analyzed quality of life (QoL) with a
questionnaire and found that almost all patients experienced QoL improvement after one
week of tVNS therapy [Ylikoski J, personal communication]. In an earlier study we
demonstrated by magnetoencephalography (MEG) acute neuromodulative effects of tVNS
on evoked auditory cortical responses supporting the idea that tVNS similarly to VNS with
implanted electrodes has the potential to enhance neuronal plasticity and, thus, to reverse
the maladaptive neuronal plasticity in the auditory cortex [11]. Therapeutic modulation of
gamma-band oscillations with vagus nerve stimulation has been recently reported in
epileptic patients. tVNS successfully also modulates tinnitus-related beta- and gamma-
band activity and thus could have potential as a treatment method for tinnitus [17].
This study did not investigate the therapeutic efficacy of tVNS for tinnitus. However, our
preliminary experience from the follow up of patients included in this study indicates that
the great majority of patients receiving a combination of tVNS and sound therapy, clearly
benefit from that therapy. This would be in accordance with a recent study reporting that
VNS paired with tones might be a promising novel treatment for chronic tinnitus [18]. On
the other hand, another recent clinical study using tVNS did not report improvement of
tinnitus with tVNS alone, although the therapy was found to be safe [19]. We also have
now clinical experience on the long-term use of tVNS by a few patients as three of our
patients have used tVNS daily for more than three years without any adverse effects. They
continue using the device (60-90 minutes per day) because of subjective benefits.
Currently, at the same setting where the present study was performed, we offer tVNS
treatment for all our patients who show THI scores 50 or over. We regard this as an
alternative to a possible need for e.g. tranquilizers.
The results of the present study should be interpreted with great caution because they
only represent a retrospective case series. However, the consistent improvement of HRV -
a seemingly useful marker of mental stress – in 90% of our patients suggests that tVNS
might be a useful therapeutic means in severe tinnitus. This study encourages further
controlled clinical studies on the usefulness of tVNS in tinnitus. More importantly, this
study offers additional support to the idea, that tVNS might offer a new, targeted
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therapeutic tool for patients in whom sympathovagal imbalance is involved. Further, tVNS
would be patient-friendly and of low-cost. Also a more general effect of tVNS on
sympathetic activity was recently demonstrated in healthy subjects. In a sham-controlled
study, active tVNS increased HRV already during one 15-minute treatment session, while
sham treatment did not result in any kind of change in HRV [20]. Vagus nerve stimulation
is an attractive method in the field bioelectric medicine, because high vagal activity has
been considered to indicate good health and high level of well-being [3-5]. Our study
suggests, that tVNS might offer a novel therapy for tinnitus related mental stress but it may
have therapeutic potential also in a wider spectrum of illnesses.
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Legends for the Tables and Figures:
Table 1. Baseline tinnitus profile data in 97 patients with moderate or severe tinnitus.
Table 2. One-minute deep breathing test (1-min DBT) HRV data of 97 patients with
moderate or severe tinnitus before (PRE) and after (tVNS)  the test tVNS-stimulation.
The 1-min DBT parameters reported here are: HRV age; Flexibility = E-I, difference
between the highest and the lowest heart rate within a breathing cycle; Dynamics  =
RMSSD,  root of the mean square of successive differences; Tone = mean HR in DBT.
Figure 1. A. The pretreatment HRV recording showed sympathetic preponderance
indicated by low values in variability of R-R intervals. Active tVNS significantly increased
the averaged variability of R-R intervals. B. tVNS increased HRV as measured by R-R
interval variability in 73 (75%) out of the 97 patients. In 20% HRV was decreased and in
5% it remained unchanged.
Figure 2. A. The averaged HRV age (64 years) was higher than the chronological age (48
years) as measured by variability of R-R intervals. Active tVNS significantly decreased the
averaged HRV age (from 64 to 56 years). B. After the test tVNS stimulation HRV age was
decreased in 70% of the patients.
Figure 3. Various parameters of HRV (Dynamics, Flexibility, Tone) can be graphically
presented as shown here: A. A large triangle indicates a good HRV with high vagal activity
= parasympathetic preponderance and a very small triangle indicates  poor
parasympathetic function. B. Averaged results of HRV measurements in 97 patients
showed a rather small triangle (red), indicating poor parasympathetic function. With a short
term (15 min) tVNS treatment this triangle was enlarged (blue), indicating improved
parasympathetic function.
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Dynamics  = RMSSD,  root of the mean square of successive differences; Flexibility = E-I,
difference between the highest and the lowest heart rate within a breathing cycle; Tone =
Mean HR in DBT (deep-breathing test)
